<DOC>
	<DOCNO>NCT01260116</DOCNO>
	<brief_summary>This study go determine efficacy , tolerability safety ziprasidone 120 schizophrenic patient depressive symptom . The study carry 2 mental center China . Subjects require attend center screening , baseline , Weeks 1 , 2 , 4 ,6 8 early termination visit . At screening , patient underwent psychiatric physical examination , standard lab test , Electrocardiograph . At baseline , continue eligible , begin ziprasidone 20 mg twice daily . Depending response tolerability , ziprasidone could gradually escalate maximum 80 mg twice daily .</brief_summary>
	<brief_title>Efficacy Safety Ziprasidone Treat Depressive Symptoms Patients With Schizophrenia</brief_title>
	<detailed_description>Primary objective The primary objective evaluate efficacy ziprasidone treatment depressive symptom patient schizophrenia . Secondary objectives The secondary objective evaluate efficacy safety tolerability ziprasidone treatment schizophrenic patient depressive symptom . Study design This study go determine efficacy , tolerability safety ziprasidone 120 schizophrenic patient depressive symptom . The study carry 2 mental center China . Subjects require attend center screening , baseline , Weeks 1 , 2 , 4 ,6 8 early termination visit . At screening , patient underwent psychiatric physical examination , standard lab test , Electrocardiograph . At baseline , continue eligible , begin ziprasidone 20 mg twice daily . Depending response tolerability , ziprasidone could gradually escalate maximum 80 mg twice daily . Dosage/Administration At baseline subject receive study drug accord follow regimen : Day 1-2 : ziprasidone 20 mg twice daily . Day 3-4 : ziprasidone 40 mg twice daily . Day 5-6 : ziprasidone 60 mg twice daily . Day 7-Week 8 : ziprasidone 40 , 60 80 mg twice daily . At visit 3 ( week 1 ) dosage study drug titrate base clinical status subject safety tolerability study drug . Subjects receive study drug food supervision . Treatment Duration It 's 8 week ' study . There 7 visit study . Visit 1 screen visit ; Visit 2 baseline visit ; Visit 3 Week 1 ; Visit 4 Week 2 ; Visit 5 Week 4 ; Visit 6 Week 6 ; Visit 7 Week 8 .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>( 1 ) .Firstepisode nonrefractory recurrent male female inhospitalized subject ( age 18 65 year ) diagnosis schizophrenia minimum score 70 Positive Negative Syndrome Scale ( PANSS ) randomization . Firstepisode define duration illness onset psychotic symptom range 3 day 36 month without systemic treatment . Refractory defined failure experience therapeutic response acute exacerbation follow adequate trial market antipsychotic agent two occasion two year prior study entry . ( 2 ) .Patients meet DSMIVTR criterion schizophrenia diagnose `` 295.XX schizophrenia '' . ( 3 ) .Patients CDSS total score 5 screen visit baseline visit . ( 4 ) .Patients guardian ability understand provide inform consent examination , observation , evaluation process specify protocol , sign inform consent base full understanding trial . ( 1 ) .Patients receive systemic treatment antipsychotic antidepressant within 12 week prior inform consent . ( 2 ) .Women pregnant , possibly pregnant , breastfeed . ( 3 ) .Patients psychotic symptom clearly due another general medical condition direct physiological effect substance . ( 4 ) .Patients meet DSMIVTR criterion substancerelated disorder within 3 month ( 90 day ) prior inform consent ( exclude caffeine nicotinerelated disorder include abuse benzodiazepine ) ( 5 ) .Patients receive ECT treatment within 8 week prior inform Consent . ( 6 ) .Patients use supplement contain centrallyacting substance ( tryptophan , St. John 's wort ) within 4 week prior inform consent . ( 7 ) .Patients unstable thyroid disorder ( hypothyroidism , hyperthyroidism ) receive thyroid treatment within 3 month ( 90 day ) prior inform consent . ( 8 ) .Patients consider unresponsive clozapine ( 9 ) .Patients significant risk develop severe adverse event . Patients medical condition would interfere assessment safety efficacy course study , history condition . For example , patient diagnose complication serious hepatic , renal , cardiac , hematopoietic disorder , describe , within 4 week prior inform consent screen period Hepatic disorder : Total bilirubin≥3.0 mg/dL , AST ( GOT ) ALT ( GPT ) ≥2.5 time upper limit normal level Renal disorder : Creatinine ≥ 2 mg/dL Cardiac disorder : patient know history QT prolongation ( include congenital long QT syndrome ) ; patient recent acute myocardial infarction ; patient uncompensated heart failure ( 10 ) .Patients know history complication allergy ziprasidone quinolinoneskeleton compound ( 11 ) .Patients history complication neuroleptic malignant syndrome ( 12 ) .Patients represent significant risk commit suicide ( 13 ) .Patients history complication organic brain disorder convulsive disorder , epilepsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Efficacy , safety , ziprasidone , depressive symptom , schizophrenia</keyword>
</DOC>